Clinical Trials
2 trialsNCT02414139 2024-03-20
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Novartis
Phase 2 Completed
NCT03240393 2018-07-26
Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)
Novartis
Phase 2 Withdrawn